|
| Tuesday, 13 July 2010, 15:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
SINGAPORE, July 13, 2010 - (ACN Newswire) - Researchers from the Institute of Chemical and Engineering Sciences (ICES), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR), were awarded two of the successful eight projects selected for funding by GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB), under the GSK-Singapore Partnership for Green & Sustainable Manufacturing, with a further two selected projects being ICES - university collaborations. The awards were presented in a ceremony on 2 July 2010. The joint funding is to support research in green and sustainable manufacturing practices and to establish Singapore as a centre of excellence in sustainable pharmaceutical manufacturing. Other award recipients were from Nanyang Technological University (NTU) and the National University of Singapore (NUS). These eight projects will receive close to US$3.5 million in funding.
The research is funded by the GSK-EDB US$35 million joint fund to grow Singapore's capabilities and talent in green and sustainable manufacturing and healthcare policy. The joint fund is part of GSK-Singapore 10-year Strategic Roadmap to address the industry's challenges and co-create innovative solutions. Established in 2002, ICES has research programmes spanning from chemistry and chemical engineering sciences, analytical characterisation and measurement to develop advanced technology for the petrochemical, general chemical, fine chemical and pharmaceutical industries.
Imagine how our environment and health can benefit if common chemicals around us are produced by green methods. With his project: "Develop cost-effective and eco-safe manufacturing technology for pharmaceuticals and fine chemicals", Dr Chen Anqi of ICES will develop new methods for amide synthesis which are innovative, green and efficient to reduce production costs and waste generation, leading to cost savings in the long run that will also benefit consumers.
Another project by ICES' scientist, Dr Jayasree Seayad: "Pharmaceutical and specialty chemicals synthesis", is to develop new sustainable methods of producing chemical structures which are very common in fine chemicals and pharmaceuticals. Current methods involve the use of hazardous compounds and produce large amounts of waste. Dr Seayad's new methods of bonding will make use of readily available chemicals traditionally regarded as unreactive and to join them together directly without using hazardous materials. This could make significant improvements to the overall manufacturing processes in the chemical and pharmaceutical industries by minimising the use of hazardous reagents and waste generation and improving production efficiency.
Many of the currently available and newly-discovered medicines have low or very low solubility in water, so they are poorly absorbed by the human body. For many medical treatments, such as for pain-relief, migraine, anti-allergy and anti-emetic, a fast and effective response is important for the patient.
One of the joint projects between NUS and ICES, "Making more efficiently absorbed medicines", aims to reduce the amount of drug that has to be taken by patients and therefore reduce the amount of materials and energy required in their production. The project, which is headed by Associate Professor Reginald B.H. Tan, who is also a research programme manager in ICES, uses cost effective ingredients and novel processing technologies to produce stable and more water soluble forms of pharmaceutical products.
Another research collaboration between ICES and NUS is a project called "Enantioselective biotransformations for sustainable pharmaceutical production: enzyme discovery, engineering, and synthetic application", led by Prof. Li Zhi of NUS and co-led by Dr. Liu Zhibin, a Research Fellow of ICES. The project aims to develop new enzymes with unique and high selectivity and special substrate range to benefit pharmaceutical synthesis.
Dr Keith Carpenter, Executive Director of ICES, commented: "I am very proud that our researchers have been recognised in this way and have received these awards and I congratulate them. I would also like to congratulate EDB and GSK for their very far sighted commitment to solving this extremely important global problem".
About the Institute of Chemical and Engineering Sciences (ICES)
Institute of Chemical and Engineering Sciences (ICES) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 2002, its mission is to carry out world class scientific research, to develop novel technology and to nurture creative scientists and engineers to support economic growth in Singapore and to make a positive difference to society. The research area covers chemistry and chemical engineering science, combined with advanced analytical characterisation and measurement to develop state of the art technology for the petrochemical, general chemical, fine chemical and pharmaceutical industries. www.ices.a-star.edu.sg.
Contact:
Hera Adam
Corporate Communications
ICES, A*STAR
Tel: +65 6796 3894
Fax: +65 6873 4805
Email: adamhc@scei.a-star.edu.sg
Topic: Awards
Source: A*STAR
Sectors: Chemicals, Spec.Chem, Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Sept 30, 2021 16:00 HKT/SGT |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Apr 5, 2019 18:00 HKT/SGT |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| More news >> |
 |
|
|
|
